Sanofi chief defends cancer drug Zaltrap; FDA unveils a litany of problems at NECC;

@FiercePharma: Pfizer won't report earnings on Tuesday as planned, thanks to Hurricane Sandy. More | Follow @FiercePharma

> Sanofi ($SNY) CEO Christopher Viebacher argued against the Memorial Sloan-Kettering doctors who weighed in against using the colorectal cancer treatment Zaltrap. Report

> The FDA released disturbing details of unsanitary conditions at the compounding pharmacy implicated in a deadly meningitis outbreak. Report

> France's Ipsen raised its outlook for the year after posting a 5% increase in third-quarter revenue on strong sales of specialty drugs. Report

> Chinese officials say they are considering plans to push merger activity in the pharmaceutical sector. Report

> Abbott Laboratories ($ABT) said it would tender for as much as $7.7 billion in bonds as it raises $16 billion in debt for its split into two companies. Report

> India's Sun Pharmaceutical is waiting for FDA approval for its version of Doxil, the Johnson & Johnson ($JNJ) cancer drug whose supplies are now being restored. Report

Medical Device News

 @FierceMedDev: Hospira faces a Class I recall for its Symbiq infusion system. More | Follow @FierceMedDev

 @MarkHFierce: Drug eluting stents have benefits in people over age 80, acc. to the XIMA study. More | Follow @MarkHFierce

 @DamianFierce: Patheon is spending $255M on softgel specialist Banner Pharmacap. More | Follow @DamianFierce

> Abbott launches massive bond issue to fuel split. Item

> Verax raises $3.3M for blood Dx. News

Biotech News

 @FierceBiotech: Human heart simulated on world's fastest supercomputer. More | Follow @FierceBiotech

 @JohnCFierce: Survey: Many docs will be slow to switch to biosimilar mAbs. More | Follow @JohnCFierce

 @RyanMFierce: Five3, maker of cancer genomics software, takes off from UCSC labs. More | Follow @RyanMFierce

> Principia platform earns $12.5M tranche from A-list venture players. News

> GSK antes up Viiv stake, grabs control of potential HIV blockbuster. Story

CRO News

> Patheon buys softgel specialist for $255M. Item

> Small CROs band together to better compete. Story

> Clinipace raises $9M to staff up after acquisition. Article

> Quintiles eyes first global trial for Indonesia. News

Biotech IT News

> Five3, maker of cancer genomics software, takes off from UCSC labs. News

> Human heart simulated on world's fastest supercomputer. Article

> Swedish bioinformatics group grabs $840K to fuel growth, report says. Story

> Accelrys acquisition hunt continues with $30M Aegis deal. Item

And Finally... It's not unprecedented for CEOs to exhort their employees to vote Republican; it was a Big Pharma tactic in 2000, Forbes reports. Report

 

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.